SPPL2B

Across TCGA pan-cancer cohorts, SPPL2B mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SPPL2B data layer compared with 24 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SPPL2B mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated SPPL2B expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where SPPL2B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	II,III,IV	0.792	0.443	.005	21	view →
CCRCC	OS	Median	All	1.000	0.884	.012	8	view →
LUAD	OS	Tertile	All	1.000	0.966	.039	6	view →
LSCC	DFS	Median	All	0.678	0.845	.022	2	view →
GBM	OS	Tertile	All	0.238	0.601	.042	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SPPL2B–PDAC (OS)

Open the PDAC breakdown →